002223 · SZSE · China
yuyue.com.cnFinancials as of FY2025
Sells respiratory devices to Chinese hospitals under government approvals that take years to replicate.
What this company is and how it runs — written from structure, not news.
Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. makes respiratory devices — oxygen concentrators, CPAP machines, nebulizers — that Chinese hospitals use to treat patients, and sells them as an interconnected system that shares a common sensor platform and data protocol across every device type. Before any single model can be sold in China, the NMPA requires a clinical validation study at a designated Chinese hospital, and those studies take 12 to 24 months regardless of how large Yuyue's factory in Jiangsu is, so the portfolio of approved models the company has already built represents years of queued regulatory work that no new competitor can compress by spending more money. Because the devices share common firmware, each new registration also validates the underlying platform, which means a hospital trying to swap out even one device type must wait 18 months for a competitor's product to clear its own study — and replacing the full portfolio means running that cycle separately for each device type. The entire structure depends on the NMPA keeping that registration process in place: if regulators created a faster approval pathway for competing domestic manufacturers, the 18-month replacement friction that keeps hospitals locked in would disappear, because the lock-in is the queue, not the hardware.
How does this company make money?
The company earns money each time a hospital or distributor buys a device, with payment collected within 30 to 60 days of sale. It also sells consumable accessories needed to keep devices running, and replacement parts for the installed base of respiratory equipment already in use at hospitals and in homes.
What makes this company hard to replace?
Hospital procurement teams need any replacement device to carry its own NMPA registration that matches existing respiratory therapy protocols — a process that takes 18 months per device type. Switching the full ecosystem means going through that cycle for oxygen concentrators, nebulizers, and CPAP machines separately. Staff also have to be retrained on each new equipment type, adding further cost and disruption on top of the regulatory wait.
What limits this company?
The company can build devices in Jiangsu faster than the government approval process allows them to sell new ones. Every new device model must wait in the same mandatory study queue at designated Chinese hospitals, which takes 12 to 24 months no matter how much factory capacity sits idle. Production can grow, but the launch calendar cannot.
What does this company depend on?
The company cannot operate without NMPA Class II medical device manufacturing licenses for its Jiangsu facilities, electronic components from Shenzhen suppliers, medical-grade silicone and plastics meeting ISO 10993 biocompatibility standards, oxygen concentrator compressor components, and blood pressure sensor modules.
Who depends on this company?
Chinese hospitals rely on the company's devices to run oxygen therapy — if supply stopped, those procedures would halt. Home healthcare distributors who rent out oxygen concentrators would have no units to offer. Rural Chinese clinics that use the portable diagnostic devices for blood pressure monitoring, often in areas with no specialist doctors nearby, would lose access to that equipment entirely.
How does this company scale?
Device assembly can be expanded by adding production lines in Jiangsu as demand grows. But each new product model still needs its own government safety study at a designated Chinese hospital, which takes 12 to 24 months regardless of how large the factory becomes. Manufacturing scales; the approval pipeline does not.
What external forces can significantly affect this company?
China's aging population is pushing more respiratory care into homes rather than hospitals, which expands demand for the company's devices. US-China trade tensions create risk for the electronic components imported for device manufacturing. Chinese healthcare reform policies that favor domestic device suppliers in public hospital purchasing work in the company's favor — but could shift if policy priorities change.
Where is this company structurally vulnerable?
If China's NMPA changed its rules to shorten mandatory study periods, accept trial data from non-designated hospitals, or created a fast-track approval lane for competing domestic manufacturers, the 18-month requalification burden that keeps hospitals tied to the existing product ecosystem would shrink or disappear — and with it, the main reason hospitals cannot simply switch suppliers.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Two structural conditions align: (1) a multi-year price band exists where the stock has, on at least two separated occasions, stopped declining and bounced upward, and (2) current price is back inside or just above that zone after a meaningful drawdown from peak. The retest is a real one — the stock is not at a new all-time high being measured as a low.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
What the company actually pays, and whether its own cash supports it.
The reported statements, read against the company's own industry.
5 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Three observations have aligned: most-recent-quarter total cash is in the upper portion of its mapped range against most-recent-quarter total debt, EBITDA-to-total-liabilities is in the upper portion of its mapped range, and FCF-to-total-liabilities is in the upper portion of its mapped range.
Three observations co-occur: long-term debt decreased year-over-year in each of the last four fiscal years, total cash at MRQ is at least equal to total debt, and the industry-benchmarked equity ratio is in its elevated range. The configuration describes past LT-debt reduction consistency alongside cash-vs-debt position and equity-heavy capital structure.
How is this stock valued?
Retained earnings are a large share of total assets; net income was positive in each of the last 5 fiscal years; shareholders' equity is in the upper part of its industry's equity-to-assets range.
Three observations co-occur: price is several standard deviations below its one-year mean, the company has reported positive net income every year for three years, and book value has increased every year for four years. The set describes a depressed-price profile alongside fundamental stability and equity accumulation.
Three observations co-occur: price is several standard deviations below its one-year mean, the company has reported positive net income every year for three years, and the equity ratio is in the elevated industry-benchmarked range. The configuration describes a depressed-price, profitable, equity-funded profile.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph